目的 探討復(fù)方苦參注射液聯(lián)合醋酸甲地孕酮治療子宮內(nèi)膜癌的臨床療效。方法 選取2013年4月-2015年8月在臨高縣人民醫(yī)院婦產(chǎn)科接受治療的子宮內(nèi)膜癌患者88例,根據(jù)治療方案的差別分為對(duì)照組和治療組,每組各44例。兩組患者均給予必要的基礎(chǔ)治療。對(duì)照組口服醋酸甲地孕酮片,160 mg/次,1次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注復(fù)方苦參注射液,20 mL加入0.9%生理鹽水250 mL中,1次/d。兩組患者均連續(xù)治療4周。治療后比較兩組患者近期療效,觀察生存質(zhì)量的改善和不良反應(yīng)發(fā)生情況。結(jié)果 治療后,對(duì)照組客觀緩解率(ORR)為43.18%,臨床獲益率(CBR)為70.45%,治療組ORR為65.91%,CBR為88.64%,兩組ORR、CBR比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,對(duì)照組和治療組生存質(zhì)量改善率分別為75.00%和90.91%,差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療過(guò)程中,對(duì)照組不良反應(yīng)例數(shù)明顯高于治療組,差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方苦參注射液聯(lián)合醋酸甲地孕酮治療子宮內(nèi)膜癌效果顯著,可顯著改善患者生活質(zhì)量,具有一定的臨床推廣應(yīng)用價(jià)值。

Recently, the morbidity of breast cancer, ovarian cancer, pancreatic cancer, and other solid tumors has increased year by year, and there is still lack of effective drugs in clinic. As the first poly ADP-ribose polymerase inhibitor for human cancer therapy, preclinical studies show that rucaparib can significantly inhibit breast cancer, ovarian cancer, and other solid tumors. Clinical studies show that rucaparib has good safety and effectiveness. The drug situation, background, route of synthesis, preclinical, and clinical trials researches of rucaparib are reviewed in this paper.